Arvinas Financials - Benzinga

Arvinas Inc

ARVNNASDAQ

Trade with Public

Trade with Public

$7.79

-0.04-0.51%

가까이에: Sep 23, 5:00 PM EST

$7.79

-0.04-0.51%

프리마켓: 8:31 AM EST

개요 뉴스 실적 전망 이벤트 목표가재무심리 지분 현황 비교 옵션 주식 보고서

Arvinas Financials

Arvinas (ARVN) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

PRO
Arvinas Q2 EPS $2.58 Beats $(0.44) Estimate, Sales $249.700M Beat $32.542M Estimate

Arvinas (NASDAQ:ARVN) reported quarterly earnings of $2.58 per share which beat the analyst consensus estimate of $(0.44) by 686.36 percent. This is a 407.14 percent increase over losses of $(0.84) per share from the

Benzinga Newsdesk

PRO
Arvinas Announces Re-Prioritization Of Portfolio Following Strategic Review; Plans To Complete Phase 1 Monotherapy Dose Escalation Trial And Share Data In 2026; Plans To Seek Out-Licensing Agreement For Additional Clinical Trials Of ARV-806; Expects Cash Position As Of March 31, 2026 To Fund Operations Into Second Half Of 2028

Following a strategic review of its pipeline, the Company has made the decision to re-prioritize its portfolio. As previously disclosed, in the second quarter of 2026, the Company announced that it had completed dose

Benzinga Newsdesk

These Analysts Increase Their Forecasts On Arvinas After Q1 Results

Arvinas Inc (NASDAQ:ARVN) reported Q1 losses of 90 cents/share, missed analyst estimates. Rigel Pharmaceuticals (NASDAQ:RIGL) announced global licensing agreement with Arvinas and Pfizer (NYSE:PFE) for oral PROTAC drug VEPPANU. Arvinas shares rose 1.7% on Wednesday and analysts have raised price targets.

Avi Kapoor

Earnings Scheduled For May 12, 2026

Benzinga Insights

PRO
Arvinas Q1 EPS $(0.90) Misses $(0.87) Estimate, Sales $15.600M Miss $18.097M Estimate

Arvinas (NASDAQ:ARVN) reported quarterly losses of $(0.90) per share which missed the analyst consensus estimate of $(0.87) by 3.45 percent. This is a 178.95 percent decrease over earnings of $1.14 per share from the

Benzinga Newsdesk

Earnings Breakdown: Arvinas Q4

Benzinga Insights

© 2026 Benzinga | All Rights Reserved